Gel-based activity profiling determined that KLK2 and KLK3 are highly activated in the presence of dihydrotestosterone (DHT) and KLK14 is deactivated by DHT but rescued by the advanced PCa drug and androgen receptor (AR) antagonist, enzalutamide. Here, KLK14 is linked to posterior cortical atrophy.